ERGOLOID MESYLATES
Clinical safety rating: safe
Animal studies have demonstrated safety
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
| Metabolism | Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect. |
| Excretion | Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose. |
| Half-life | 2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals. |
| Protein binding | Approximately 90% bound to albumin. |
| Volume of Distribution | 1.5-2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: less than 10% due to extensive first-pass metabolism. |
| Onset of Action | Oral: Effects on mental status may be observed within 3-5 weeks of continuous therapy; not immediate. |
| Duration of Action | Effects are sustained over time with chronic dosing; no acute duration defined as continuous therapy is required for clinical benefit. |
| Molecular Weight | 1215.4 Da (as the trimethanesulfonate salt; parent base ~830 Da) |
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
| Dosage form | TABLET |
| Renal impairment | Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%. |
| Pediatric use | Not established; safety and efficacy not determined in pediatric patients. |
| Geriatric use | Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects. |
| 1st trimester | Avoid; ergot derivatives are oxytocic and may cause uterine contractions, increasing risk of miscarriage. |
| 2nd trimester | Avoid; potential for uterotonic effects and fetal hypoxia due to vasoconstriction. |
| 3rd trimester | Avoid; contraindicated near term due to oxytocic properties and risk of uterine hyperstimulation. |
Clinical note
No significant drug interactions Not for use in the treatment of psychosis or acute mental disorders.
| Placental transfer | Ergot alkaloids cross the placenta; case reports of fetal distress and neonatal withdrawal. |
| Breastfeeding | Ergoloid mesylates are excreted into breast milk; potential for adverse effects such as vomiting, diarrhea, and vasospasm in the infant. Use is not recommended during breastfeeding. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Nausea |
| Serious Effects |
Hypersensitivity to ergot alkaloidsPregnancyPeripheral vascular diseaseCoronary artery diseaseSevere hypertensionHistory of psychosis
| Precautions | Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism. |
| Food/Dietary | Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration. |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated) |
| Teratogenic Risk | Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions. |
| Fetal Monitoring | Monitor uterine activity (tocography) if used during pregnancy; fetal heart rate monitoring for signs of distress. In postpartum, monitor for excessive bleeding or vasospasm. Assess maternal blood pressure and signs of ergotism (numbness, tingling, chest pain). |
| Fertility Effects | Ergoloid mesylates may inhibit prolactin secretion, potentially impairing ovulation and fertility. Use for hyperprolactinemia-induced infertility may restore ovulation but risk of pregnancy requires contraception during therapy. |
| Clinical Pearls | Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence. |
| Patient Advice | Take exactly as prescribed; do not double doses if missed. · Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness. · Avoid smoking and caffeine as they may worsen vasoconstriction. · May cause dizziness or fainting; avoid driving until you know how the drug affects you. · Do not use with other ergot alkaloids or triptans. |